Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
09:10am, Wednesday, 12'th Feb 2025
Biogen Inc. (BIIB) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago.
Biogen's stock hit by soft guidance and a decline in sales of MS drugs
07:48am, Wednesday, 12'th Feb 2025
Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
06:50am, Wednesday, 12'th Feb 2025
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The
Drugmaker Biogen forecasts 2025 profit below expectations
06:47am, Wednesday, 12'th Feb 2025
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.
Royalty Pharma Announces R&D Funding Collaboration With Biogen
06:30am, Wednesday, 12'th Feb 2025
Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus Royalty Pharma to provide
Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
03:22am, Wednesday, 12'th Feb 2025
Biogen Inc. BIIB will release its fourth-quarter financial results, before the opening bell, on Wednesday, Feb. 12, 2025.
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
02:46pm, Monday, 10'th Feb 2025
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Seeking Clues to Biogen (BIIB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:21am, Friday, 07'th Feb 2025
Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
11:05am, Wednesday, 05'th Feb 2025
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
10:35am, Monday, 03'rd Feb 2025
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
Europe to review safety data for Eisai-Biogen Alzheimer's drug
06:46am, Friday, 31'st Jan 2025
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
06:30am, Friday, 31'st Jan 2025
TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Wednesday, 29'th Jan 2025
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
10:06am, Monday, 27'th Jan 2025
The FDA's approval is based on simulation data from multiple studies showing that maintenance dosing with Biogen???s Leqembi every four weeks prolongs biomarker benefits.
Sage rejects Biogen's $469 million takeover offer
09:28am, Monday, 27'th Jan 2025
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen.
